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Abstract 
 
AcrB is a major multidrug exporter in Escherichia coli and other Gram-negative bacteria. Its 
gate loop, located between the proximal and the distal pockets, have been reported to play 
important role in the export of many antibiotics. This loop location, rigidity and interactions with 
substrates have led recent reports to suggest that AcrB export mechanism operates in a 
sequential manner. First the substrate binds the proximal pocket in the access monomer, then 
it moves to bind the distal pocket in the binding monomer and subsequently it is extruded in the 
extrusion monomer. Recently, we have demonstrated that the gate loop is not required for the 
binding of Erythromycin but the integrity of this loop is important for an efficient export of this 
substrate. However, here we show that the antibiotic susceptibilities of the same AcrB gate loop 
mutants for Doxorubicin were unaffected, suggesting that this loop is not required for its export, 
and we demonstrate that this substrate may use principally the tunnel-1, located between 
transmembranes 8 and 9, more often than previously reported. To further explain our findings, 
here we address the gate loop mutations effects on AcrB solution energetics (fold, stability, 
molecular dynamics) and on the in vivo efflux of Erythromycin and Doxorubicin. Finally, we 
discuss the efflux and the discrepancy between the structural and the functional experiments 
for Erythromycin in these gate loop mutants. 
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1. Introduction 
 
AcrB is the principal efflux transporter in E. coli, located in the inner membrane of the bacteria, 
and plays an important role in capturing and expelling its substrates mainly from the periplasm 
[1-5]. AcrB has an extremely wide substrate specificity consisting of structurally diverse and 
unrelated compounds, including antibiotics, detergents, dyes, organic solvent, and biofuels [3, 
6-10]. AcrB belongs to the superfamily of resistance nodulation and cell division (RND) 
transporters, and functions as a homotrimer where large conformational changes take place 
between the resting state, symmetric trimer in the absence of substrate, and the active state, 
asymmetric trimer in the presence of substrate [11-14].  
 
Crystallographic studies of AcrB in complex with antibiotics have shown that these substrates 
bind either the proximal pocket in the access/loose monomer (access binding pocket) or the 
distal pocket in the binding/tight monomer (deep binding pocket) [11, 15, 16]. The observed 
binding of large substrates (Erythromycin (ERY) and Rifampicin) to the proximal pocket versus 
small substrates (Doxorubicin (DOX) and Minocyclin) binding to the distal pocket, and the 
presence of a loop (gate/switch loop), of ~ 10 amino acids, (Fig. 1A) separating these two main 
binding pockets have provided further insight into AcrB-substrate interactions and inspired the 
idea of a sequential or stepwise export mechanism for AcrB efflux activity [15, 16]. This implies 
the substrate binds the proximal pocket, then the distal pocket and subsequently to be extruded 
out of the cell via TolC. Such mechanism raises the question on the gate loop role and 
importance in this efflux mechanism, as it lies precisely between the proximal pocket and the 
distal pocket. In particular, the conformational change from the access monomer to the binding 
monomer results in an increased space within the distal pocket while a decreased space at the 
proximal pocket, and hence the gate loop may have direct implication toward substrates 
binding and export, as previously stated [15, 16].  
 
Several reports have shown that mutation or deletion of residues at the gate loop affect AcrB 
export activity of several substrates to variable extent [15-20]. Crystallographic investigations of 
AcrB mutations at the gate loop, such as G616N and G616P-G619P, have been reported to 
indicate that this loop flexibility may play an important role in substrate transport during the 
undergoing conformational changes by the monomers between the access/loose, binding/tight, 
and extrusion/open states [15, 16]. In fact, it was reported that in G616N mutant the gate loop 
conformation in the access monomer resembles the one of the binding monomer in AcrB, and 
in G616P-G619P mutant the gate loop conformation in the binding monomer resembles the 
one of the access monomer in AcrB. This induced rigidity in these gate loop mutants was 
directly linked to the decrease in their antibiotics resistance [15, 16]. To rationalize the effect of 
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these gate loop mutations on AcrB substrates export, structural investigations at atomic 
resolution are crucial to underline the important interactions between these mutants and the 
substrates.  
 
To understand the structural and functional importance of the gate loop in AcrB export activity, 
recently we have reported the structures of two mutants of this loop in the presence and 
absence of ERY; the triple mutant F615A-F617A-R620A (AAA), and the deletion mutant 
F615G-[G616-R620] (Loop), as they cover several of the reported mutations of the loop and 
making a large deletion of the loop, that has never been reported before. We have shown for 
the first time that this loop is not required structurally for the binding of ERY [21]. However, 
several aspects concerning the gate loop mutations effect on AcrB fold, stability and dynamics 
in solution, the trimeric state symmetry, the export of small substrate such as DOX, other 
explanations for the discrepancy between the structural and functional results for ERY, and 
further important structural details within these AcrB-ERY complexes were not addressed.    
 
Consequently, in this work we will address several questions on the importance of the gate loop 
in the export of ERY and DOX, including its effect on AcrB (1) trimer symmetry, (2) solution fold 
and stability, (3) solution molecular dynamics, (4) antibiotics resistance, and (5) in vivo efflux. 
To address these questions, we have used X-ray crystallography to solve the structures of the 
mutants in the symmetrical trimer state, we have investigated AcrB and mutants fold and 
stability in solution using CD spectroscopy, we have used MD simulation to study AcrB and 
mutants molecular dynamics in solution, and we have performed their antibiotic susceptibility, 
minimum inhibitory concentration (MIC), and in vivo efflux assays.  
 
2. Materials and Methods 
 
2.1. Expression and purification of AcrB and mutants 
 
WT AcrB plasmid, called pETHisAcrB, was used for the protein expression as previously 
described [22]. pETHisAcrB was used as template to produce our gate loop mutants, F615A-
F617A-R620A (AAA), and F615G-(G616-R620) (Loop). Amino acids substitutions and 
deletion were achieved using 5′ phosphorylated primers, and standard mutagenesis protocols. 
Mutations were verified by sequencing the amplified mutant plasmids. To express WT AcrB and 
mutants E. coli cells lacking endogenous AcrB gene were used. Cells were grown at 30 oC in 
2TY medium containing 50 mg/l carbenicillin to an OD600 of 0.6, when 0.5 mM IPTG was 
added for 4 h. Cells harvested by centrifugation were resuspended in 20 mM Tris pH 8.0, 500 
mM NaCl, 5% glycerol, 2 mM MgCl2. Cells were broken by 30k psi passage through a cell 
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disruptor. After centrifugation at 10,000xg for 10 min at 4 oC, the supernatant is centrifuged at 
140,000xg for 1 h. The membrane pellet was resuspended and solubilised in 10 mM KPi pH 
8.0, 100 mM NaCl, 10 mM imidazole and 1.0% n-dodecyl -maltoside (DDM) for 1 h at 4 oC. 
Then the mixture  was centrifuged for 1 h at 145,000xg and the supernatant was applied onto a 
Ni2+-NTA agarose column pre-equilibrated with buffer A (20 mM KPi pH 8.0, 100 mM NaCl, 10 
mM imidazole, 0.02% DDM). The column was washed with buffer B (20 mM KPi pH 8.0, 300 
mM NaCl, 50 mM Imidazole, 0.02% DDM), and the proteins were eluted with buffer C (20 mM 
KPi pH 8.0, 100 mM NaCl, 300 mM Imidazole, 0.02% DDM). Proteins were buffer exchanged 
into 20 mM Tris pH 8.0, 100 mM NaCl, 0.1 or 0.03% DDM, using an Amicon 100 kDa molecular 
weight cut-off concentrator (Millipore). 
 
2.2. Crystallization of AcrB and mutants  
 
To search for initial hits, crystallization trials were carried out using several crystallization 
screening buffers, and using sitting drop over 96 well MRC plates (Molecular Dimensions) with 
the mixing of the protein solution and reservoir solution performed by Mosquito robot. Crystals 
were then manually optimized in 24 well plates. AcrB, AAA, and Loop crystals were grown by 
the hanging drop vapour diffusion method at 15 oC, and at protein concentrations of 27, 24, and 
20 mg/ml, respectively. The drops were made by mixing 2.0 l of protein solution with 2.0 l of 
crystallization solution, and equilibrated against 1 ml of the crystallization solution. The crystals 
were grown in buffer-1 (0.1 M ADA buffer at pH 7.4, 0.1 M Li2SO4, 10% PEG 3350), and were 
cryoprotected by stepwise addition of cryoprotectant as buffer-1 plus 22% glycerol or 25% 
ethylene glycol, before being flash-frozen in liquid nitrogen.  
 
2.3. X-ray diffraction collection, structure phasing and refinement 
 
X-ray diffraction data for screening and checking crystals quality were collected at Diamond 
Light Source (Didcot, UK). X-ray diffraction data were collected at 100 K on beamline PXIII at 
Swiss Light Source (SLS) at the Paul Scherrer Institut (Villigen PSI, Switzerland). X-ray data 
sets were indexed and integrated using iMosflm [23] and scaled using Scala or Aimless in the 
CCP4 suite [24]. The structures were solved by molecular replacement using Phaser [25] or 
Molrep [26]. Structures were solved using PDB file 3D9B [27] containing residues 1-1033. All 
Structures refinement were performed in two steps: First we used the recently reported 
refinement strategy combining the Rosetta sampling methodology and energy function with 
reciprocal-space X-ray refinement in Phenix [28], and then we continue the refinement using 
Phenix [29]. The structures were completed with iterative rounds of manual model-building with 
Coot [30] and refinement in Phenix. Figures were prepared using PyMol (www.pymol.org). 
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2.4. Circular dichroism spectroscopy and thermal unfolding  
 
CD spectra were collected on an Aviv Model 410 CD spectrophotometer.  Far-UV CD spectra 
were collected from 200 to 260 nm using a 1 mm cell path length and a 3 s averaging time.  
Thermal unfolding data were collected at 222 nm in the temperature range of 16 oC to 82 oC.  
Samples were placed in a 2 mm cuvette and heated in increments of 2 oC. All the experiments 
were carried out in 20 mM Tris pH 7.4, 100 mM NaCl, 0.03% DDM. The protein concentration 
was held constant at 5-10 M.  All CD measurements were corrected by subtracting the buffer 
spectra. 
 
The unfolding experiments were fitted to a two-state model, and hence the CD unfolding data 
were fitted to 
S = SN + (SU - SN)/(1 + exp(+GNU/RT)) 
 
where S is the observed signal, and SN and SU are the CD signals for the unfolded and the 
native protein, respectively.  GNU is the free energy difference of the unfolding reaction.  Both 
the SN and SU were assumed to depend linearly on the temperature and the denaturant 
concentration, and to retain this linearity in the transition region. 
 
For the thermal unfolding we assume that the heat capacity, Cp
o, is temperature independent 
in the range of measurement [31], and hence the free energy of unfolding is 
 
GNU(T) = Hm + Cp
o (T - Tm) – T {Hm/Tm + Cp
o ln(T/Tm)} 
 
Where Tm is the melting temperature and Hm is the enthalpy difference at Tm.    
 
2.5. Antibiotic susceptibility and efflux assays 
 
Single colonies of acrB deficient E. coli strain MC1061 harbouring AcrB and mutants, AAA and 
Loop, plasmids were grown overnight at 37 oC in 2TY medium with 4g/ml chloramphenicol 
and 25g/ml carbenicillin. Bacteria growth was inoculated into 10 ml 2TY medium and grown at 
37 oC to an OD at 600 nm of ~ 0.6-0.8, and then incubated for further ~ 30 min after adding 0.5 
mM IPTG. Cells adjusted OD at 600 nm of ~ 0.06 were transferred to 100 l 2TY medium 
containing 4g/ml chloramphenicol and 25g/ml carbenicillin, and ERY or DOX at 32 g/ml and 
KAN at 4 g/ml for the drug susceptibility test, and different concentrations after successive 
dilution of a starting concentration of ERY, DOX, and KAN of 2 mM, 1.14 mM and 2 mM, 
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respectively. The bacterial growth was measured using 96-well flat-bottomed plates (Nunc, 
Thermo Scientific), and a Synergy HTX Multi-Mode microplate reader (BioTek Instruments). 
After the overnight growth the drug susceptibility tests were plotted and the MIC’s for ERY and 
DOX were determined. The experiments were performed in triplicate. 
 
Similarly, for drug efflux assays we have grown cells at 37 oC to an OD at 600 nm of ~ 0.6-0.8, 
and then incubated for further ~ 30 min after adding 0.5 mM IPTG. The cells were then 
collected, washed twice with 100mM potassium phosphate buffer (pH 7.5 and containing 5mM 
MgSO4) and then resuspended in the same buffer with an adjusted OD at 600 nm of 22. Each 
assay was performed in 96-well, flat-bottomed black plates (Nunc, Thermo Scientific) using a 
final cell volume of 100 ul, and doxorubicin (Sigma-Aldrich) was added to a final concentration 
of 29 M, and for the competition assays, 29 M ERY or KAN was added, as previously 
reported [16]. The fluorescence of DOX was measured using a Synergy HTX Multi-Mode 
microplate reader (BioTek Instruments) with an excitation wavelength of 485 nm and an 
emission wavelength of 620 nm. The fluorescence intensity decreased in a time-dependent 
manner owing to the accumulation of DOX in the cells, and the decrease in fluorescence 
intensity was prevented when DOX was expelled by an efflux pump. All the experiments were 
3-4 times duplicated and the average data were plotted for the figures clarity. 
 
2.6. Molecular dynamics simulation and trajectory analysis 
 
Molecular dynamics simulations were performed using the AMBER package [32]. R32 crystal 
form structures of AcrB and mutants were used as starting structures. We performed our MD 
simulations using only the symmetric trimer structures of AcrB and mutants, as it is well 
accepted to be the resting state of the protein, where D407 and D408 are deprotonated. 
Consequently, if any structural effect that may occur due to the mutations will be better 
captured, and assessed in subsequent conformational changes of the proteins, than in an 
already functional state such as the asymmetric trimer where the protonation states of D407 
and D408 should be taken into account [33]. The proteins were inserted in a pre-equilibrated 
138 x 138 Å 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE) membrane 
bilayer. AcrB’s and mutants’ central transmembrane cavity were manually filled by 13 POPE 
molecules. Clashes between POPE molecules and the proteins were removed. The AMBER 
force field parm99 was used for the protein and the TIP3P parameters for water [34], and 
GAFFlipid force field was used for POPE [35]. Standard protonation states were selected for all 
titratable residues. The proteins and POPE bilayer were submersed in a water box with Na+ 
ions to neutralize the system. The final simulation system for AcrB consisted of 90,344 atoms of 
the protein and POPE, 45 Na+ ions, 275,538 atoms of water, which make a total of 365,927 
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atoms. AAA simulation system consisted of 90,242 atoms of the protein and POPE, 48 Na+ 
ions, 275,559 atoms of water, which make a total of 365,849 atoms. Loop simulation system 
consisted of 90,101 atoms of the protein and POPE, 48 Na+ ions, 275,559 atoms of water, 
which make a total of 365,708 atoms. 
 
The time step was 2.0 fs with bonds fixed by SHAKE [36], the temperature was 300 K, van der 
Waals interactions were truncated at 10.0 Å, while electrostatic interactions were fully 
calculated with the Particle Mesh Ewald method [37]. After performing energy minimization only 
on the water molecules, the whole system was then energy minimized, and a 200 ps of solvent 
equilibrations at 300 K were calculated including the Na+ ions. Following equilibration, a 
trajectory of 10 ns was calculated for each molecular system. All the MD trajectories analysis, 
including the principal component analysis (PCA), was performed using AMBER package. 
Since the first three eigenvectors account for almost the total motions, we have projected our 
MD trajectories into the three-dimensional subspace defined by the top three principal 
components (X1, X2, and X3).  
 
2. 7. Accession numbers 
 
The atomic coordinates and structure factors of AcrB, AAA, and Loop structures in space 
group R32 have been deposited to the Protein Data Bank with the accession code 4ZLJ, 4ZLL, 
4ZLN, respectively. 
 
3. Results 
 
3.1. Structures of symmetric and asymmetric trimers of AcrB, AAA, and Loop 
 
Apo structures of AcrB and its gate loop mutants, AAA and Loop, were solved in R32 space 
group for the symmetrical trimer as previously reported [27, 38, 39]. Detailed structures 
statistics are summarized in Table S1. Comparison of our structures in R32 space group with 
previously reported structures shows that our structures are consistent with symmetric form of 
AcrB (Fig. 1B), and have high structural similarities as reflected low RMSD’s (< 1.05 Å) 
calculated on the whole main chain for each structure comparison (Table S2). The structures of 
AcrB and the mutants in R32 crystal form show that the gate loop mutations have no effect on 
the trimer state symmetry, as we recently reported for the asymmetric trimer of these mutants 
in P21 crystal form [21]. 
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Previously we have reported the structures of AcrB and its gate loop mutants in P21 space 
group, in the presence and absence of ERY (Fig. 1B) [21], however several important 
structural details, involving the gate loop and thus their implication in the activity of AcrB, were 
not reported, in particular the detergent molecules binding and the ERY binding to the access 
monomer of the second trimer in our P21 structures. Details on Ni
2+ presence and coordination 
are summarized in Supplementary Materials. Consequently, we will present and discuss these 
structural details in the following sections. Although there are similarities between our P21 form 
structures and the asymmetric trimer structures solved in P1 and C2 space groups, our 
structures present dissimilarities with their crystal packing [11, 12, 16]. For each trimer in our 
structures the presence of 5 trimers in close contact occurs, including direct contact between 
the docking domains, in a head to head configuration that has never been observed in other 
AcrB crystal packing (Fig. S1).  
 
Importantly, comparison of the structures of AcrB and its mutants, AAA and Loop, in either the 
apo form, in R32 and P21, or the complex form with ERY, in P21, revealed an overall highly 
conserved structures, and in particular in their export channel where the gate loop is located 
(Fig. 1B, and Table S2). This clearly shows that mutation or deletion of the gate loop, 
independently of the crystal forms, does not disrupt the overall fold, the trimer symmetry, and 
the 3D structure of AcrB. 
 
3.2. Detergent binding to AcrB, AAA, and Loop 
 
In the AcrB and mutants structures we have solved previously in space group P21 [21], one 
detergent molecule (Dodecyl--D-maltoside, DDM, here called DDM-1) per monomer was 
found in the protein structures, in P21 form, in either the absence or presence of ERY (Fig. 2A, 
2B, and Fig. S3). DDM-1 binding site consists predominately of residues S530, R536, R540, 
and Y541, and its binding revealed the presence of several potential hydrogen bonds (Table 
S6, S7). These observations suggest that DDM-1 has conserved binding mode. Interestingly, 
overlay of recently reported AcrB-AcrZ structure [40] with our structure monomers shows DDM-
1 and AcrZ to share similar binding site with further similarities in their potential hydrogen bonds 
formation with residues S530, R536, R540, and Y541 (Fig. 2). Note that although the side 
chain of R536 is absent in AcrB-AcrZ structure, due to its close proximity to S37 in AcrZ 
strongly suggests that a hydrogen bond is highly possible to form between R536 and S37 (Fig. 
2E). Consequently, taking into account the substantial specificity of DDM-1 binding, the sugar 
group in DDM-1 could be a potential lead fragment to block AcrB-AcrZ complex formation [41] 
and therefore to possibly disrupt the efflux pump activity, as suggested recently [42]. 
Remarkably, although we have used the exact same protein purification protocol and the 
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proteins samples have similar amount of DDM, no such DDM-1 binding has been observed in 
our R32 structures. This may suggest that either the crystal packing or the crystallization 
conditions may affect substantially the binding of DDM-1 molecules. Indeed, in P21 crystal form 
there is a hydrogen bond network formation between R536 and DDM-1 between AcrB 
monomers in crystal contact. This is absent in R32 crystal form as the nearest contact distance 
between monomers in crystal contact is between R536 and E962, however, a hydrogen bond 
between these donors and acceptors is ruled out as the nearest distance between is ~ 4.3 Å.  
 
Surprisingly, in the presence of ERY the structures of AcrB and mutants revealed the presence 
of a second DDM molecule (DDM-2) binding only to monomer A and D within the groove 
formed by transmembrane 8 and 9 (TM8/TM9) (Fig. 3, and Fig. S4), which defines the 
entrance to tunnel-1 for AcrB substrates [11, 43]. While both trimers in our P21 crystal form are 
similar [21], strikingly the binding of DDM-2 in monomer A and D are substantially different (Fig. 
3B, 3C). In monomer D, DDM-2 binds substantially higher in tunnel-1 as compared to its 
binding in monomer A, which resulted in different potential hydrogen bonds formation (Table 
S7). Comparison of our DDM-2 binding in our P21 structures with previously reported C2 
structure with DDM-2 [15], shows highly conserved binding site for DDM-2 in either monomer A 
or D, nevertheless our DDM-2 in monomer D has clearly moved upward (Fig. 3E, 3F). Again, 
although we have used the exact same protein purification protocol and the proteins samples 
have similar amount of DDM, no such DDM-2 binding has been observed in our R32 structures. 
A rational explanation for this observation comes from the comparison of our R32 structure with 
P21 structure in the presence of ERY. Indeed, the DDM-2 molecule is in direct clash with the 
loop connecting the PC2 domain to TM8 in R32 structure, as shown in Fig. 3G, and also when 
compared with other R32 structures (Fig. S5).  
 
Since the binding of DDM-2 have been reported by others in similar binding site and binding 
mode, it clearly substantiates the importance of this binding site for possibly other substrates of 
AcrB [15, 43], as we have shown for DDM-1 binding that mimics AcrZ binding to AcrB [40]. 
 
3.3. Substrate binding to AcrB, AAA, and Loop 
 
Although we succeeded to co-crystallize AcrB and its gate loop mutants with ERY and DOX in 
P21 space group, the X-ray diffraction data resulted in electron density maps that either have 
weak or merely no electron density to be assigned for either ERY or DOX around their reported 
binding sites or elsewhere in the structure [15, 16]. Similar situation has been reported for the 
binding of minocycline to AcrB mutant, G616N, at resolution of 2.9 Å [15]. Consequently, we 
have soaked the crystals, in P21 space group, of the proteins grown in the presence of ERY or 
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DOX in solution containing ERY or DOX. Subsequently, the X-ray diffraction data of the protein 
crystals in the presence of ERY revealed electron densities clearly identified for ERY in the 
proximal pocket [21]. Close inspection of the electron density maps elsewhere in the structure 
and in particular around A385-F386 loop revealed no possible electron density for bound ERY, 
as it was reported for the binding of linezolid to AcrB [44]. Unfortunately, with DOX we were 
unable to observe any plausible or realistic electron density for this substrate. 
 
Structural comparison and analysis of ERY’s binding to our AcrB, AAA, and Loop structures 
and the reported  AcrB-ERY structure [16], revealed high similarity in the binding mode of ERY 
in the proximal pocket (Fig. 4), as well as overall similar intermolecular interactions (Table S8). 
However, subtle but real differences were observed between ERY binding to the access 
monomers, A and D, in each trimer. Indeed, AcrB and mutants complex structures show ERY 
to superimpose well in monomer A as compared to monomer D (Fig. 4). Interestingly, such 
difference seems to correlate with the difference of DDM-2 binding to monomer A and D (Fig. 
3B, 3C). Hence we speculate on the existence of some kind of influence between DDM-2 
binding site and the proximal pocket where ERY binds, in particular when DDM-2 moved 
upward in the monomer D (Fig. 3D).   
 
3.4. Antibiotics susceptibilities of AcrB, AAA, and Loop 
 
The surprising conserved binding of ERY to the mutants in our structures, and in particular with 
Loop mutant, prompted us to investigate the in vivo involvement of the AcrB’s gate loop using 
the antibiotic susceptibility and efflux transport for cells with AcrB and mutants genes. We have 
performed drug susceptibility test, drug efflux assay, and minimal inhibitory concentration (MIC) 
experiments for ERY, DOX for comparison as a smaller substrate, and Kanamycin (KAN) as a 
control since it is not a substrate of AcrB. Similar expression levels of AcrB and its gate loop 
variants were confirmed using western blot analysis (Fig. S6). In the absence of antibiotics, the 
cell growth of AcrB and mutants were similar to each other (Fig. S7). In the presence of ERY, 
at subinhibitory concentration of 32 g/ml, the cell growth of the mutants were clearly affected 
and followed the decreasing order of AcrB > AAA > Loop (Fig. 5A). However, at the same 
subinhibitory concentration of DOX the overall cell growth of AcrB and mutants were nearly 
similar, and in the presence of KAN, at subinhibitory concentration of 4 g/ml, the cell growth of 
AcrB and mutants were similar (Fig. 5A). The MIC’s results show the mutants to be highly 
susceptible to ERY when compared to AcrB, while the DOX susceptibility for AcrB and mutants 
were identical (Table 1).  
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To further investigate the gate loop effect on the AcrB substrates efflux, we have performed in 
vivo efflux of DOX, and ERY and KAN in the presence of DOX. The substrate efflux activity of 
AcrB and mutants was monitored by their ability to expel DOX that penetrated the cells. As 
shown in Fig. 5B, the control acrB-deficient cells (acrB) accumulated DOX, as its 
fluorescence in the medium showed a time-dependent quenching. Instead the efflux of DOX by 
AcrB and mutants shows no fluorescence quenching, as DOX penetrating the cells was 
expelled to the medium (Fig. 5B). Similar result is observed for the efflux KAN by AcrB and 
mutants, where no substantial changes in DOX fluorescence took place, as expected since 
KAN is not a substrate of AcrB. Interestingly, the inhibition of DOX efflux (accumulation in the 
cells) in the presence of ERY shows similar DOX fluorescence quenching for AcrB, as 
previously reported [16], and mutants (Fig. 5B). While this implies the existence of efflux 
competition between DOX and ERY, it is worth noting that there is no substantial difference 
between AcrB and the mutants as observed for ERY susceptibility test (Fig. 5A). 
 
These results strongly suggest that AcrB’s gate loop is required for the well optimized and 
efficient export of ERY in vivo, while this loop is not required for the optimized DOX export.  
 
3.5. Gate loop mutations effect on the solution fold and stability of AcrB 
 
Taking into account the conflicting results between the structural and functional involvement of 
the gate loop in the export of ERY, we have addressed the effect of the gate loop mutations on 
the fold and stability of AcrB in solution, as such solution energetics may substantially affect 
AcrB export activity in vivo while undetected in the crystal structures analysis. Consequently, 
we have used CD spectroscopy to collect the far-UV CD spectra and the thermal unfolding data 
of AcrB and mutants, AAA and Loop. The far-UV CD spectra of AcrB and mutants show no 
differences (Fig. 6A), suggesting that the mutants kept conserved secondary structures content 
and most probably overall similar structures to the WT in solution, as reported by our crystal 
structures (Fig. 1). The thermal denaturation results of the gate loop mutants revealed small 
shift in their melting curves as compared to the WT (Fig. 6B). A minor stability of the WT over 
the mutants is observed as shown by the Tm difference of ~ 3 oC (Table 2). However, such 
relatively small difference in Tm suggests an overall similar stability between the WT and the 
mutants, and in particular at physiological temperature (Fig. 6B).  Hence, these results 
demonstrate that AcrB’s gate loop mutations do not affect the fold and the overall stability of 
AcrB in solution, which is in good agreement with our reported X-ray structures of these 
mutants in either R32 or P21 crystal form [21].   
  
3.6. Gate loop mutations effect on the molecular dynamics of AcrB 
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We performed MD simulations of AcrB and its gate loop mutants to assess the effect of these 
mutations on AcrB overall, intra- and inter-domains molecular dynamics. To assess the overall 
proteins conformational space sampling achieved during the MD simulations we performed 
principal component analysis (PCA) for the porter domain (PD) and the docking domain (DD) 
(Fig. 1A). The 3D plot of each monomer’s PD/DD of each protein conformation, as projected 
into X1, X2 and X3 modes, shows a good conformational sampling amount by the proteins 
(Fig. 7). However, for better comparison between the proteins, 2D plots of X1/X2, X1/X3, and 
X2/X3 were carried out, and revealed the location of the starting conformations (Fig. S8). 
Although we have minimized our crystal structures and equilibrate the molecular systems prior 
to the MD trajectories calculations, these conformations were more often far from the 
conformation clusters sampled by the proteins (Fig. S8). This suggests that the proteins in 
solution may populate conformations that are slightly different to their crystal structures, as 
recently also reported for the asymmetric trimer of AcrB [45]. 
 
The RMSD’s of the individual monomers with respect to their starting conformations were 
calculated, and nearly all the profiles show an overall similar trend in reaching a plateau, or 
nearly about as for 1 monomer in either AcrB or AAA, and being stable during the MD 
trajectories (Fig. 8A). Interestingly, for all proteins the RMSD profiles show two monomers to 
evolve nearly identically while the third monomer exhibits different behaviour. Strikingly, when 
we compare the calculated RMDS’s between the monomers in the asymmetric trimer of AcrB 
similar observation occurs, namely RMSD(A/B), RMSD(A/C), and RMSD(B/C) were 1.96 Å, 
3.24 Å, and 3.22 Å, respectively. The structural changes during the export activity of AcrB can 
be assessed by the conformational changes at PC1 (containing the gate loop) and PC2 
domains within the monomers, which are involved in the AcrB functional rotating mechanism 
[11, 12]. Consequently, we have calculated the distance between PC1 and PC2 domains 
during our MD trajectories for AcrB and mutants (Fig. 8B). With the exception for monomer B of 
AAA and monomer C of Loop, the overall trend in these distances were fairly similar for all the 
proteins. However, similar trend found in RMSD profiles (Fig. 8A) can also be observed here, 
as two monomers evolve nearly in similar way while the third monomer exhibits different 
behaviour (Fig. 8B), which is modest in AcrB while prominent in AAA and more stronger in 
Loop. 
 
The conformational changes that AcrB undergoes between symmetric to asymmetric trimer is 
well accepted to be directly linked to its export activity, due to the proton translocation at its 
transmembrane domain which plays a major role in such structural change [11-13]. In this work 
our structures were prepared for the MD simulations calculations with deprotonated D407 and 
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D408, which should lead to no conformational change, since the symmetric trimer is the resting 
state in the absence of ligand [46]. To check on the presence of any conformational change 
between the monomers in our proteins, we looked closely at the central small helix containing 
Q112, as in the extrusion monomer (monomer C in the asymmetric trimer) this helix is highly 
inclined when compared with the other monomers, where their helices are nearly perpendicular 
to the membrane plane. Hence, we calculated the angles between Q112 at each monomer 
using C atoms (Fig. S9). Surprisingly the calculated angles for the last 2 ns in all the proteins 
show one angle to be higher than the other two (Table S9), reporting similar trend as with the 
RMSD and PC1-PC2 distance profiles (Fig. 8). Interestingly, comparison of our angles with 
those of the asymmetric trimer revealed similar trend except for the other two angles, as they 
were slightly different to each other (Table S9). Our data clearly point to a tendency in the 
molecular dynamics behaviour of these symmetric trimers to somehow break from the strict 
symmetrical conformation. Beyond the implication of crystal packing forces, these molecular 
dynamics behaviour of AcrB and mutants, resulting in structural shift from the X-ray structures, 
suggest that the water motion within these proteins may play a role in such behaviour. Indeed, 
the water residency and movement were reported to play important role in the export 
mechanism of AcrB [47, 48]. 
 
Our AcrB and mutants in complex with ERY structures show that ERY binds specifically to the 
proximal pocket and in particular to K290 and S134 surrounded by S132-S135 (Fig. 4, Table 
S8). Hence to investigate the effect of the gate loop mutations on ERY binding site we 
calculated the RMSD’s of the Serine-loop (S-Loop, S132-S135) (Fig. S10), and the hydration 
change at residues K290 and S134, using the radial distribution function (RDF) profiles 
providing the probability of finding water molecules at a given distance from the residue of 
interest. Overall similar RMSD’s profiles are observed for the S-loop, with minor difference in 
monomer A (Fig. S10B). RDF profiles show an overall similar hydration of either S134 or K290, 
with small differences at distances above 4 Å, and the first hydration shell peak is centred 
around 2.8 Å for S134, while it is around 3.0 Å for K290  (Fig. 8C-D, Fig S11).  
 
4. Discussion 
 
Understanding how the efflux pump AcrAB-TolC works, and hence its contribution to the 
multidrug resistance in Gram-negative bacteria, necessitates a good understanding of the 
export mechanism of AcrB. This relies mainly on studying AcrB interactions with its substrates 
at atomic resolution. However, X-ray crystallography investigations of AcrB-substrate 
interactions has proven very challenging, since structures of AcrB with only five antibiotics 
(ERY, DOX, Minocycline, Rifampicin, and Puromycin), with the exception of an inhibitor ABI-PP 
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that shares similarities with the binding of DOX and Minocycline, and recent structures of the 
periplasmic part of AcrB in complex with MBX compounds and Rhodamine 6G, were reported 
[11, 15, 16, 49-51]. To further understand the AcrB export mechanism, we have investigated 
the role and the importance of the gate loop in AcrB interactions with ERY and DOX for their 
binding and in vivo export. In fact, several reports have shown that mutation or deletion of 
residues at the gate loop can affect AcrB export activity of several substrates to variable extent 
[16-19]. However, no direct structural evidence on the interaction of the substrates with these 
mutants has been reported prior to our work [21]. Consequently, we have characterized the 
mutations effect of the gate loop, AAA and Loop, on AcrB’s ERY binding, structure, trimer 
symmetry, solution fold, solution stability, molecular dynamics, and antibiotics resistance and 
efflux.  
 
Our recent and present work results revealed unexpected findings on the role and importance 
of the gate loop in AcrB export mechanism. Indeed, it is unexpected to observe the binding of 
ERY to AAA and Loop to be similar to the WT [21], while substantial increase in ERY 
susceptibility for the mutants was observed (Fig. 5, Table 1). Strikingly, despite the deletion of 
the gate loop in Loop mutant, which results in further available space in the export channel to 
accommodate at least another ERY molecule in the access monomers (monomers A and D), 
and possibly the binding of ERY to the binding monomers (monomers B and E), the binding of 
ERY to the mutants is similar to its binding to the WT. This strongly suggests that ERY binds 
specifically to the proximal pocket in the access monomer. Interestingly, although ERY has to 
be translocated deeper beyond the proximal pocket, no alternative ERY binding site could be 
observed. In fact, we have predicted that ERY can bind favourably to the distal pocket using 
molecular docking and MD simulation (data not shown), as previously reported [52]. The 
multisite binding proximal and distal pockets of AcrB are large enough to physically 
accommodate more than one substrate, such as the possible binding of DOX and Minocyline in 
the distal pocket (see details in Fig. S12). However, although mutations in the distal pocket 
have been reported to dramatically increase the susceptibility of ERY [17], and the presence of 
several polar residues (S46, Q67, N68, N70, Q89, S128, E130, S167, D174, Q176) beyond the 
proximal pocket, which could provide alternative binding site(s) for ERY, our Loop-ERY 
structure revealed no such possible binding sites for ERY. These observations suggest that 
beyond the proximal pocket, ERY’s binding site, the translocation of ERY in the export channel 
of AcrB is possibly highly transient in nature, resulting in no stable AcrB-ERY interaction to be 
observed experimentally, at least in light of our findings [21]. This idea of highly transient 
binding of ERY is well strengthen by the recent proposed hypothesis of “multisite drug-
oscillation” where the drug molecule oscillates between several drug binding sites in the large 
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binding pockets of AcrB (proximal and distal), and the suggestion that high molecular mass 
drugs, such as ERY, may be occluded without specific binding in the distal pocket [53].  
 
Comparison with the reported structure of AcrB-ERY revealed structural differences at the gate 
loops around A618-R620 residues (Fig. 4) [16]. Overlay of AcrB and AAA structures in the 
presence of ERY shows the gate loop in AAA moved upward around A618 without affecting the 
binding of ERY, in particular in monomer A (Fig. 4). G616N and G616P-G619P mutations were 
reported to have increased the rigidity of the gate loop, in particular for G616P-G619P, which 
was claimed to explain their increased ERY and DOX susceptibilities [15, 16]. Our mutant, AAA 
cannot confer a rigid gate loop and hence the increase of ERY susceptibility for this mutant 
could not be explained by the rigidity of this loop. In fact, our MD simulations show the RMSD 
and RMSF of the gate loop in each monomer of AAA having higher structural variations and 
flexibility, respectively, than the WT loops, which is in line with rather flexible loop behaviour 
(Fig. S13).  Furthermore, antibiotics resistance investigation of G616N reported that substrates 
with higher minimal projection areas, such as ERY, are less well transported than those with 
lower minimal projection areas due to the gate loop rigidity [20]. This may suggest that either 
the increase of the flexibility or the deletion of the gate loop should enhance the export of ERY. 
However, the triple alanine mutation and the deletion of this loop in AAA and Loop mutants, 
respectively, show ERY to be less well exported in AAA and much less exported in Loop (Fig. 
4, Table 2). Hence, beyond how well ERY is exported when compared to other smaller 
substrates, the gate loop is somehow required for its well optimized export by AcrB. Indeed, 
either high or low flexibility of the gate loop resulted in less well exported ERY, which suggests 
that a well tuned and optimized flexibility, as present in the WT, is necessary to achieve better 
and well optimized export of ERY.  
 
Interestingly, these gate loop mutations have no substantial effect on DOX transport (Fig. 4, 
Table 2), which suggests that DOX may use alternative translocation routes to the tunnel-2, 
where it has to interact with the gate loop as recently reported [15, 20]. Tunnel-1 where DDM-2 
binds AcrB and mutants, in monomer A and D (Fig. 3B, 3C), has been suggested to be one of 
AcrB substrates’ translocation routes [11, 43]. Indeed, L674W and A677W mutations were 
shown to reduce significantly DOX efflux activity, while nearly undetectable for S462K mutation 
[16]. In fact, mutations of AcrB were reported to substantially increase the export of biofuel 
molecules; in particular T678A mutation increased the export of -pinene by 320% [10]. In 
addition, I63F and I671T mutations were reported to increase the susceptibility of several lower 
molecular weight drugs, which bind the distal pocket, while nearly unchanged susceptibility of 
many large AcrB substrates was observed [54]. These mutations are located nearby and above 
the sugar head group in DDM-2 molecule, as well as part of the tunnel-1 route toward the distal 
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pocket (Fig. 3). In addition, molecular docking and energy minimized AcrB structure with DOX 
in DDM2 binding site shows the binding similarity between these substrates, in particular at the 
sugar group part of DDM-2 (Fig. S14). Furthermore, the possibility that binding of DDM-2 may 
induce the subtle differences of ERY binding in monomer A and D (Fig. 4), suggests that 
tunnel-1 is indeed an active pathway for substrates such as detergent DDM and DOX. Hence, 
together these observations suggest that DOX may use both tunnel-1 and tunnel-2 as part of its 
translocation pathway [10, 15, 16, 20]. Nevertheless, the absence of any substantial effect of 
the gate loop mutations on the DOX export may be due to the combination of its translocation 
via tunnel-1 and its binding to the distal pocket overriding the binding of the proximal pocket as 
a result of the “multisite drug-oscillation” idea [53]. The above results and observations suggest 
that DDM-2 binding in tunnel-1, in monomer A and D, may be highly relevant for hydrophobic 
substrates having tunnel-1 as part of their translocation route, such as possibly detergent and 
DOX, as also recently suggested [53].  
 
We have shown that the AcrB gate loop is not required for the binding of ERY (Fig. 4), while it 
is required for its well optimized export by AcrB (Fig. 5, Table 1). The efflux of ERY as 
indirectly measured by the fluorescence quenching of DOX, revealed similar efflux transport 
between AcrB and mutants (Fig. 5B).  This shows that DOX efflux transport is decreased due 
to the competition with ERY, confirming that ERY and DOX use similar translocation pathway in 
AcrB export channel; at and beyond the distal pocket. Nevertheless, this result did not image 
the expected order of the observed increase of ERY susceptibility of the mutants (Fig. 5A, 
Table 1). Three explanations to this finding are possible; first, in the presence of ERY, DOX 
may principally use tunnel-1 instead of tunnel-2, used by ERY, to move toward the distal pocket 
without having to compete strongly with ERY and hence the observed ERY susceptibility of the 
mutants becomes virtually similar. Further evidence for this explanation, as explained above, 
was recently reported for AcrB I63F and I671T mutations [54], as well as previous reports on 
mutations such as L674W, A677W and S462K mutations [16] and T678A mutation [10], which 
are within the tunnel-1 route. Second, the lower molecular weight, size, and shape of DOX as 
compared to ERY may benefit DOX to translocate far easily and possibly faster than ERY as 
recently reported for other substrates [10, 20], which in turn may not be dramatically affected by 
the ERY susceptibility of the mutants resulting in virtually similar efflux of ERY by AcrB and 
mutants. Third, ERY export by the mutants maybe enhanced to a similar level by the presence 
of DOX and hence no difference is observed for DOX export, as recently reported for the strong 
increase of the efflux of nitrocefin in the presence of Arg -naphthylamide [55]. Although, the 
mechanism by which this enhanced or stimulated export occurred is yet to be explained, in our 
case taking into account the large space within the distal pocket, which may accommodate for 
at least 2 substrates simultaneously (Fig. S12), and the transient nature of ERY binding to the 
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distal pocket may suggest that the binding of DOX to the distal pocket promotes the 
translocation of ERY toward its extrusion. This will result in ERY export to be similar for AcrB 
and the mutants.     
 
Our structural data clearly show that AcrB gate loop (i) does not interfere with the binding of 
ERY (binding to the access monomer, to the proximal pocket, and with similar binding mode), 
and (ii) does not dictate the location of the binding site of ERY (proximal pocket versus distal 
pocket). This clearly suggests that the gate loop is not required for the binding of ERY. Also our 
mutants’ structures reveal no effect on AcrB trimer symmetry, as their asymmetric and 
symmetric trimers were similar to the WT. Our solution energetics investigations show that the 
gate loop mutations did not affect the fold and the overall stability of the proteins. However, 
while the overall dynamics of AcrB and mutants may seem similar (RMSD, proximal binding 
site hydration), moderate to substantial effect was observed at their monomers intra-domain 
molecular dynamics (PC1 and PC2 domains, gate loop). In contrast, our functional results 
provide an opposite picture to the structural and solution energetics results (fold, stability), 
since the mutants showed an increase of their ERY susceptibility, which means that the gate 
loop is required for the well optimized export of ERY by AcrB. Furthermore, while reported 
structures of AcrB-DOX complexes exhibit the presence of 1 contact residue between the gate 
loop and DOX at F617 in the proximal pocket and at F615 in the distal pocket [11, 15], yet our 
results provide evidence that the gate loop is not required for the export of DOX. Consequently, 
this may highlight the flexibility between DOX translocation routes as it may use tunnel-1 and/or 
tunnel-2 depending on the availability of the route and/or the pressure of efficient transport by 
AcrB for the survival of the bacteria. 
  
At this stage, it is not an easy task to provide an explanation, substantiated experimentally, able 
to reconcile our structural and functional results on the involvement of the gate loop in ERY 
export. However, an intuitive explanation to such discrepancy could be related to the binding 
affinities of ERY to AcrB and mutants. Indeed, our structures show that ERY binds the mutants 
similarly to AcrB, however we cannot quantify their binding affinities. Subsequently, If the 
binding affinity could be in decreasing order such as AcrB > AAA > Loop, then this may seem 
to reflect the ERY resistance assay (Fig. 5A). However, it may be questionable to assume that 
the export of ERY will follow the same trend as the binding affinities and not the opposite order 
(AcrB < AAA < Loop), when in general AcrB is highly efficient in exporting large number of 
unrelated and diverse substrates that may not bind specifically or tightly to its export channel. 
Instead, a plausible explanation for such link between the binding affinity and the export of ERY 
in these mutants may lie in the effect of these mutations on ERY binding oscillations (ERY 
oscillations between several binding sites) in the proximal pocket which in turn may affect its 
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translocation through the distal pocket [53]. This explanation also holds for DOX as it binds 
mainly the distal pocket and hence it is fair to suggest the binding affinities will be fairly similar 
resulting in similar export of DOX for AcrB and the mutants.  
 
On the other hand, the emergence of this discrepancy between our structural and functional 
results, for ERY, suggests that beyond our knowledge of AcrB export mechanism, we have to 
consider the possibility that the structural binding of a substrate to AcrB and its translocation 
through the export channel in vivo may take place through multi-conformational states 
mechanism, where several of these conformational states are unknown in our in vitro structural 
studies, due to their transient nature and kinetics. Indeed, in in vitro we observe only the most 
stable conformational state within the final stage of this multi-conformational states mechanism 
as represented by the asymmetric trimer of AcrB. Consequently, while our mutants’ structures 
show no overall difference with the WT, the conformational changes kinetics from the 
symmetric to the asymmetric trimer and beyond may hold the key to such discrepancy with our 
functional results. In fact, recent report has shown that AcrB mutation E673G increased ERY 
resistance 2 fold, while structurally no contact is detected between E673 and ERY [56]. 
Interestingly, while Q569R mutation has no effect on the resistance of ERY, as Q569 is located 
at the entrance to the proximal pocket (shortest contact ~ 10.0 Å), the double mutant Q569R-
E673G showed also no change in ERY resistance [56]. Thus, such long range effect can only 
be associated with the effect of molecular dynamics which in turn may affect the conformational 
change kinetics in these mutants. Similar conclusion could be drawn for the double mutant 
I626R-E673G which decreased ERY resistance 8 fold while I626R alone decreased ERY 
resistance 4 fold [56]. In addition, in line with this explanation, deletion of 17 residues in the 
protruding loop of AcrB, which far from either proximal or distal pockets, resulted in high 
susceptibility for ERY with 32 fold lower MIC than WT, while the fold and stability of this AcrB 
mutant were unchanged [57]. Furthermore, our MD simulations show how mutation or deletion 
of the gate loop can affect the distance between PC1 and PC2 domains which are involved in 
the export channel structure of AcrB and the conformational change between access, binding 
and extrusion monomers during AcrB’s functional rotation mechanism. This suggests that 
further in the export process time course such differences could affect the normal 
conformational change kinetics of AcrB, and hence resulting in different susceptibility for ERY 
in these gate loop mutants. Altogether these observations clearly strengthen the idea of the 
presence of conformational changes kinetics differences between these mutants leading to 
their ERY susceptibility differences.   
 
5. Conclusion  
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In summary, our work shows that AcrB’s gate loop is not required for the binding of ERY but 
required for its well optimized export by AcrB. However, this loop is not required for the export 
of DOX, suggesting that the possibility it may not be required for DOX binding since DOX 
mainly binds the distal pocket. We demonstrate that the gate loop flexibility did not enhance the 
export of ERY, which opposes recent report on the effect of rigidity of this loop on the export of 
this antibiotic. Based on our and previously reported experimental data, we show that DOX use 
tunnel-1 more often than tunnel-2 for its translocation route. To reconcile the discrepancy 
between our structural and functional results for ERY we have suggested two possible 
explanations; the mutations effect on ERY binding affinity and the conformational changes 
kinetics. Nevertheless, there are more experimental data, as presented here, along with 
observations from our molecular dynamics results, which favour the latter explanation.       
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Figure Legends: 
 
Fig. 1. Crystal structure of AcrB and gate loop mutants. (A) AcrB monomer depicting the 
docking domain (DD), the porter domain (PD), the transmembrane domain (TMD) and a close 
up view of the gate loop. (B) Structural comparison between AcrB (green) and its mutants, AAA 
(magenta) and Loop (blue), in R32 (symmetric trimer, PDB: 4ZLJ, 4ZLL, 4ZLN) and P21 
(asymmetric trimer) space groups. For the structures in P21 in the absence (- ERY) (PDB: 4ZIT, 
4ZIV, 4ZIW) or presence (+ ERY) (PDB: 4ZJL, 4ZJO, 4ZJQ) of ERY, and for clarity ERY 
molecules are not shown. Top figure is the superposition of the overall structures (only access 
monomer A for P21 structures), and bottom figure is a close-up view at the export channel 
(proximal pocket, gate loop, and distal pocket), depicting the overall structural conservation.   
 
Fig. 2. Binding of DDM-1 molecule to AcrB, AAA, and Loop in P21. (A) AcrB access monomer, 
in the absence of ERY, exhibiting the location of DDM-1 molecule (yellow sticks). (B) 2Fo – Fc 
electron density map of DDM-1 binding to monomer A (access monomer in trimer-1) and 
contoured at 1.0 . (C) Overlay of our AcrB and reported AcrB-AcrZ structures and depicting 
the overlap between DDM-1 and part of AcrZ (L28-S37). (D) Binding site of DDM-1 and its 
potential hydrogen bonds. (E) Binding of AcrZ at DDM-1 binding site, including the potential 
hydrogen bonds. 
 
Fig. 3. Binding of DDM-2 molecule to AcrB, AAA, and Loop in P21. (A) AcrB access monomer, 
in the presence of ERY (green sticks), exhibiting the location of DDM-1 and DDM-2 molecules 
(yellow sticks). (B) 2Fo – Fc electron density map of DDM-2 binding to monomer A (access 
monomer in trimer-1) and contoured at 1.0 . (C) 2Fo – Fc electron density map of DDM-2 
binding to monomer D (access monomer in trimer-2) and contoured at 1.0 . (D) Close-up view 
of ERY and DDM-2 in their binding site in tunnel 2 and 1, respectively. (E) Overlay of the 
monomer A and the access monomer from AcrB structure 4DX5 (orange and DDM-2 in blue), 
showing the similarities between DDM-2 molecules. (F) Overlay of the monomer D and the 
access monomer from AcrB structure 4DX5 (orange and DDM-2 in blue), showing the binding 
position shift of our DDM-2 molecule. (G) Overlay of the monomer A and our AcrB structure in 
R32 form. 
 
Fig. 4. Binding of ERY to AcrB, AAA, and Loop in the access monomer A (Trimer-1) and D 
(Trimer-2).  Structures overlay of the access monomer with a close up view at the binding site 
of ERY and the corresponding gate loop in AcrB (green), AAA (magenta), Loop (blue), and 
the reported structure of AcrB-ERY (pdb code 3AOC, yellow). 
 
26 
 
Fig. 5. Antibiotic susceptibility test and efflux assay for AcrB and its gate loop mutants, 
including the control acrB (cells lacking acrB gene). (A) Antibiotic susceptibility test of ERY, 
DOX, and KAN at subinhibitory concentrations. (B) DOX efflux and competitive inhibition of 
DOX efflux by ERY and KAN, as monitored by DOX fluorescence quenching. 
 
Fig. 6. Solution fold and stability of AcrB, AAA, and Loop. (A) Far-UV CD spectra. (B) Thermal 
denaturation plot of the apparent fraction of unfolded protein (Fapp) as a function of 
temperature. 
 
Fig. 7. Principal component analysis (PCA) of the porter domain and the docking domain of 
AcrB, AAA and Loop. The first three principal modes were included in the present study to 
analyze the states of the monomers A (black), B (blue) and C (red). Each data point represents 
a different conformation of the monomers. 
 
Fig. 8. Effect of the gate loop mutations on the molecular dynamics of AcrB and ERY binding 
site hydration. (A) Proteins stability as assessed by calculated RMSD’s over the C atoms. (B) 
Distance changes between PC1 and PC2 domains as calculated between their centroid using 
the C atoms. (C)  S134 backbone oxygen to water oxygen radial distribution function. (D)  
K292 side chain nitrogen to water oxygen radial distribution function.  
 
 
 
 
 
 
 
 
 
 
Table 1. Antibiotics susceptibilities of AcrB, AAA, and Loop (MIC in g/ml)  
Antibiotic acrB AcrB AAA Loop 
ERY 23 367 92 46 
DOX 10 331 331 331 
KAN 9 5 5 18 
 
 
 
 
 
Table 2. Thermal unfolding parameters  
Protein C
p
 (kcal/mol . K)
a H
m
 (kcal/mol)
a T
m
 (
o
C) T
m
 (
o
C) 
AcrB -3.69 90.12 55.0 --- 
AAA -4.82 98.91 51.7 3.3 
Loop -3.51 88.94 51.5 3.5 
a These parameters are reported for completeness  
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